Cardiovascular disease is the leading cause of death in the United States. Heart failure is a common, costly, and potentially fatal condition that is inadequately managed by pharmaceuticals. Cardiac repair therapies are promising alternative options. A potential cardiac repair therapy involves reprogramming human fibroblasts toward an induced cardiac progenitor-like state. We developed a clinically useful and safer reprogramming method by nonintegrative delivery of a cocktail of cardiac transcription factor-encoding mRNAs into autologous human dermal fibroblasts obtained from skin biopsies. Using this method, adult and neonatal dermal fibroblasts were reprogrammed into cardiac progenitor cells (CPCs) that expressed c-kit, Isl-1, and Nkx2.5. Furthermore, these reprogrammed CPCs differentiated into cardiomyocytes (CMs) in vitro as judged by increased expression of cardiac troponin T, α-sarcomeric actinin, RyR2, and SERCA2 and displayed enhanced caffeine-sensitive calcium release. The ability to reprogram patient-derived dermal fibroblasts into c-kit+ CPCs and differentiate them into functional CMs provides clinicians with a potential new source of CPCs for cardiac repair from a renewable source and an alternative therapy in the treatment of heart failure.
Get full access to this article
View all access options for this article.
References
1.
Garbern JessicaC and Lee RichardT. (2013). Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell, 12:689–698.
2.
DopplerSA, DeutschM-A, LangeR and KraneM. (2013). Cardiac regeneration: current therapies—future concepts. J Thorac Dis, 5:683–697.
3.
LaflammeMA, ChenKY, NaumovaAV, MuskheliV, FugateJA, et al. (2007). Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotech, 25:1015–1024.
4.
NelsonTJ, Martinez-FernandezA, YamadaS, Perez-TerzicC, IkedaY, et al. (2009). Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation, 120:408–416.
5.
AmadoLC, SaliarisAP, SchuleriKH, JohnSt. M, XieJ-S, et al. (2005). Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A, 102:11474–11479.
6.
KarantalisV and HareJM. (2015). Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res, 116:1413–1430.
7.
SmithRR, BarileL, ChoHC, LeppoMK, HareJM, et al. (2007). Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation, 115:896–908.
8.
BearziC, RotaM, HosodaT, TillmannsJ, NascimbeneA, et al. (2007). Human cardiac stem cells. Proc Natl Acad Sci U S A, 104:14068–14073.
9.
MishraR, VijayanK, CollettiEJ, HarringtonDA, MatthiesenTS, et al. (2011). Characterization and functionality of cardiac progenitor cells in congenital heart patients. Circulation, 123:364–373.
10.
HareJM. (2015). Where are we with cardiac cell-based repair for human heart failure?. 18th Annual Meeting of American Society of Gene and Cell Therapy. New Orleans, LA, p 64.
11.
GrensK. (2015). Hearts on Trial. The Scientist. LabX Media Group, Midland Ontario, Canada.
12.
FuJD, StoneNR, LiuL, SpencerCI, QianL, et al. (2013). Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state. Stem Cell Reports, 1:235–247.
13.
NamYJ, SongK, LuoX, DanielE, LambethK, et al. (2013). Reprogramming of human fibroblasts toward a cardiac fate. Proc Natl Acad Sci U S A, 110:5588–5593.
14.
MandalPK and RossiDJ. (2013). Reprogramming human fibroblasts to pluripotency using modified mRNA. Nat Protoc, 8:568–582.
15.
WarrenL, ManosPD, AhfeldtT, LohYH, LiH, et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 7:618–630.
16.
KimTK, SulJY, PeternkoNB, LeeJH, LeeM, et al. (2011). Transcriptome transfer provides a model for understanding the phenotype of cardiomyocytes. Proc Natl Acad Sci U S A, 108:11918–11923.
17.
XieM, CaoN and DingS. (2014). Small molecules for cell reprogramming and heart repair: progress and perspective. ACS Chem Biol, 9:34–44.
18.
SmitsAM, van OorschotAA and GoumansMJ. (2012). Isolation and differentiation of human cardiomyocyte progenitor cells into cardiomyocytes. Methods Mol Biol, 879:339–349.
19.
KuboH, JaleelN, KumarapeliA, BerrettaRM, BratinovG, et al. (2008). Increased cardiac myocyte progenitors in failing human hearts. Circulation, 118:649–657.
20.
LeeJ, BoczkowskiD and NairS. (2013). Programming human dendritic cells with mRNA. Methods Mol Biol, 969:111–125.
21.
LeeJ, BoczkowskiD and NairS. (2013). Engineering B cells with mRNA. Methods Mol Biol, 969:101–110.
22.
SmitsAM, van VlietP, MetzCH, KorfageT, SluijterJP, et al. (2009). Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: an in vitro model for studying human cardiac physiology and pathophysiology. Nat Protoc, 4:232–243.
23.
ChomczynskiP and MackeyK. (1995). Short technical reports. Modification of the TRI reagent procedure for isolation of RNA from polysaccharide- and proteoglycan-rich sources. Biotechniques, 19:942–945.
24.
KuboH, BerrettaRM, JaleelN, AngertD and HouserSR. (2009). c-Kit+ bone marrow stem cells differentiate into functional cardiac myocytes. Clin Transl Sci, 2:26–32.
25.
MonteithGR and BirdGSJ. (2005). Techniques: high-throughput measurement of intracellular Ca2+–back to basics. Trends Pharmacol Sci, 26:218–223.
26.
HeusinkveldHJ and WesterinkRHS. (2011). Caveats and limitations of plate reader-based high-throughput kinetic measurements of intracellular calcium levels. Toxicol Appl Pharmacol, 255:1–8.
27.
SongK, NamYJ, LuoX, QiX, TanW, et al. (2012). Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature, 485:599–604.
28.
DrewsK, TavernierG, DemeesterJ, LehrachH, De SmedtSC, et al. (2012). The cytotoxic and immunogenic hurdles associated with non-viral mRNA-mediated reprogramming of human fibroblasts. Biomaterials, 33:4059–4068.
29.
KhalilIA, KogureK, AkitaH and HarashimaH. (2006). Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev, 58:32–45.
30.
JanowskiE, BerriosM, CleemannL and MoradM. (2010). Developmental aspects of cardiac Ca(2+) signaling: interplay between RyR- and IP(3)R-gated Ca(2+) stores. Am J Physiol Heart Circ Physiol, 298:H1939–H1950.
31.
ChenF, DingS, LeeBS and WetzelGT. (2000). Sarcoplasmic reticulum Ca(2+)ATPase and cell contraction in developing rabbit heart. J Mol Cell Cardiol, 32:745–755.
32.
IedaM, FuJD, Delgado-OlguinP, VedanthamV, HayashiY, et al. (2010). Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell, 142:375–386.
33.
QianL, HuangY, SpencerCI, FoleyA, VedanthamV, et al. (2012). In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature, 485:593–598.
34.
MaioliM, RinaldiS, SantanielloS, CastagnaA, PigliaruG, et al. (2012). Radiofrequency energy loop primes cardiac, neuronal, and skeletal muscle differentiation in mouse embryonic stem cells: a new tool for improving tissue regeneration. Cell Transplant, 21:1225–1233.
35.
TakahashiK, TanabeK, OhnukiM, NaritaM, IchisakaT, et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131:861–872.
36.
BoisselL, BetancurM, LuW, WelsWS, MarinoT, et al. (2012). Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma, 53:958–965.
37.
DjurovicS, IversenN, JeanssonS, HooverF and ChristensenG. (2004). Comparison of nonviral transfection and adeno-associated viral transduction on cardiomyocytes. Mol Biotechnol, 28:21–32.
38.
AngelM and YanikMF. (2010). Innate immune suppression enables frequent transfection with RNA encoding reprogramming proteins. PLoS One, 5:e11756.
39.
NewtonK and DixitVM. (2012). Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol, 4: pii: a006049.
40.
LeeJ, SayedN, HunterA, Au KinF, Wong WingH, et al. (2012). Activation of innate immunity is required for efficient nuclear reprogramming. Cell, 151:547–558.
41.
BhiseNS, WahlinKJ, ZackDJ and GreenJJ. (2013). Evaluating the potential of poly(beta-amino ester) nanoparticles for reprogramming human fibroblasts to become induced pluripotent stem cells. Int J Nanomed, 8:4641–4658.
42.
KrejciE, DvorankovaB, KvasilovaA, BorskyJ, GrimM, et al. (2014). Cellular and molecular characteristics of neonatal skin: consequences for healing (734.10). FASEB J. 28.
43.
GoumansMJ, de BoerTP, SmitsAM, van LaakeLW, van VlietP, et al. (2007). TGF-beta1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro. Stem Cell Res, 1:138–149.
44.
RaynaudCM, HalabiN, ElliottDA, PasquierJ, ElefantyAG, et al. (2013). Human embryonic stem cell derived mesenchymal progenitors express cardiac markers but do not form contractile cardiomyocytes. PLoS One, 8:e54524.
45.
GershBJ, SimariRD, BehfarA, TerzicCM and TerzicA. (2009). Cardiac cell repair therapy: a clinical perspective. Mayo Clin Proc, 84:876–892.
46.
van BerloJH, KanisicakO, MailletM, VagnozziRJ, KarchJ, et al. (2014). c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature, 509:337–341.
47.
BolliR, ChughAR, D'AmarioD, LoughranJH, StoddardMF, et al. (2011). Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet, 378:1847–1857.
48.
KeithMC and BolliR. (2015). “String theory”. of c-kit(pos) cardiac cells: a new paradigm regarding the nature of these cells that may reconcile apparently discrepant results. Circ Res, 116:1216–1230.
49.
WuSM, FujiwaraY, CibulskySM, ClaphamDE, LienCL, et al. (2006). Developmental origin of a bipotential myocardial and smooth muscle cell precursor in the mammalian heart. Cell, 127:1137–1150.
50.
BoyleAJ, SchulmanSP and HareJM. (2006). Stem cell therapy for cardiac repair: ready for the next step. Circulation, 114:339–352.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
